$AKTX
Akari Therapeutics Plc Stock $aktx

$aktx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 8-K Financial Statement

#000095017024104428 Filed on September 06, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.241M	$11.36M	$5.954M
YoY Change	-62.36%	-16.05%	100.82%
% of Gross Profit
Research & Development	$3.314M	$5.450M	$3.255M
YoY Change	1.81%	-43.0%	14.17%
% of Gross Profit
Depreciation & Amortization	$0.00	$2.150K	$1.850K
YoY Change	-100.0%	22.16%	96.81%
% of Gross Profit
Operating Expenses	$5.555M	$16.81M	$9.210M
YoY Change	-39.68%	-27.21%	58.35%
Operating Profit	-$7.449M		-$4.615M
YoY Change	61.41%
Interest Expense	$51.00K	$218.0K	$86.61K
YoY Change	-41.12%	-96.02%	-40.43%
% of Operating Profit
Other Income/Expense, Net	-$109.0K	$6.580M	$6.124M
YoY Change	-101.78%	-4751.49%	-66597.18%
Pretax Income	-$7.558M	-$10.01M	-$2.999M
YoY Change	152.05%	-43.61%	-47.21%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$7.558M	-$10.01M	-$2.999M
YoY Change	152.05%	-43.61%	-47.21%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	15.85B		10.12B
Diluted Shares Outstanding	18.84B		10.12B

Balance Sheet

Concept	2024 Q2	2023 Q4	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.177M	$3.845M	$7.181M
YoY Change	-41.83%	-70.98%	-11.91%
Cash & Equivalents	$4.200M	$3.800M	$7.181M
Short-Term Investments
Other Short-Term Assets	$94.00K	$496.0K	$816.5K
YoY Change	-88.49%	398.28%	-74.49%
Inventory
Prepaid Expenses	$805.0K	$299.0K
Receivables
Other Receivables	$0.00	$75.19K
Total Short-Term Assets	$5.076M	$4.341M	$7.997M
YoY Change	-36.53%	-68.58%	-29.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$31.81K	$153.1K
YoY Change
Goodwill
YoY Change
Intangibles		$14.00K
YoY Change		-17.06%
Long-Term Investments
YoY Change
Other Assets	$11.14K	$9.200K
YoY Change		513.33%
Total Long-Term Assets	$0.00	$14.00K	$15.78K
YoY Change	-100.0%	-17.06%	-16.24%
TOTAL ASSETS
Total Short-Term Assets	$5.076M	$4.341M	$7.997M
Total Long-Term Assets	$0.00	$14.00K	$15.78K
Total Assets	$5.076M	$4.355M	$8.013M
YoY Change	-36.65%	-68.51%	-29.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.686M	$1.671M	$1.031M
YoY Change	354.68%	76.52%	-36.96%
Accrued Expenses	$1.685M	$1.566M	$2.402M
YoY Change	-29.85%	-50.26%	70.29%
Deferred Revenue
YoY Change
Short-Term Debt	$600.0K	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.779M	$4.584M	$5.232M
YoY Change	67.81%	-61.93%	71.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$230.7K
YoY Change		-70.83%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.779M	$4.584M	$5.232M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$8.779M	$4.584M	$5.232M
YoY Change	67.81%	-61.93%	71.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$240.6M	-$227.5M
YoY Change		4.62%
Common Stock	$185.4M	$176.1M
YoY Change		4.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.703M	-$229.0K	$2.781M
YoY Change
Total Liabilities & Shareholders Equity	$5.076M	$4.355M	$8.013M
YoY Change	-36.65%	-68.51%	-29.53%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023 Q2
OPERATING ACTIVITIES
Net Income	-$7.558M	-$10.01M	-$2.999M
YoY Change	152.05%	-43.61%	-47.21%
Depreciation, Depletion And Amortization	$0.00	$2.150K	$1.850K
YoY Change	-100.0%	22.16%	96.81%
Cash From Operating Activities	-$4.894M	-$6.858M	-$9.574M
YoY Change	-48.88%	-12.98%	11.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$3.517M	$3.503M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.763M	3.517M	3.503M
YoY Change	121.62%	-72.78%
NET CHANGE
Cash From Operating Activities	-4.894M	-6.858M	-9.574M
Cash From Investing Activities
Cash From Financing Activities	7.763M	3.517M	3.503M
Net Change In Cash	2.869M	-3.341M	-6.071M
YoY Change	-147.26%	-166.29%	-29.19%
FREE CASH FLOW
Cash From Operating Activities	-$4.894M	-$6.858M	-$9.574M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q3	dei	Amendment Flag AmendmentFlag	false
CY2024Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001541157
CY2024Q3	dei	Document Type DocumentType	8-K
CY2024Q3	dei	Document Period End Date DocumentPeriodEndDate	2024-09-06
CY2024Q3	dei	Entity Registrant Name EntityRegistrantName	Akari Therapeutics, Plc
CY2024Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2024Q3	dei	Entity File Number EntityFileNumber	001-36288
CY2024Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1034922
CY2024Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	22 Boston Wharf Road FL 7
CY2024Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2024Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2024Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02210
CY2024Q3	dei	City Area Code CityAreaCode	929
CY2024Q3	dei	Local Phone Number LocalPhoneNumber	274-7510
CY2024Q3	dei	Written Communications WrittenCommunications	false
CY2024Q3	dei	Soliciting Material SolicitingMaterial	false
CY2024Q3	dei	Pre Commencement Tender Offer PreCommencementTenderOffer	false
CY2024Q3	dei	Pre Commencement Issuer Tender Offer PreCommencementIssuerTenderOffer	false
CY2024Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	us-gaap	Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://www.akaritx.com/20240906#FairValueAdjustmentToDerivativeLiability
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	381649
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	654892
CY2023Q4	us-gaap	Derivative Assets Current DerivativeAssetsCurrent	0
CY2022Q4	us-gaap	Derivative Assets Current DerivativeAssetsCurrent	13000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1992458
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2562901
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2374107
CY2022Q4	us-gaap	Assets Current AssetsCurrent	3230793
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153108
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	376648
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	60000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	239699
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3681072
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9200
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1500
CY2023Q4	us-gaap	Assets Assets	2596415
CY2022Q4	us-gaap	Assets Assets	7529712
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5862435
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3618026
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3576768
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2038291
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4439235
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	720577
CY2023Q4	aktx	Insurance Financing Note InsuranceFinancingNote	631993
CY2022Q4	aktx	Insurance Financing Note InsuranceFinancingNote	921576
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	361704
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	166000
CY2023Q4	aktx	Promissory Note Current PromissoryNoteCurrent	350000
CY2022Q4	aktx	Promissory Note Current PromissoryNoteCurrent	0
CY2023Q4	aktx	Due To Related Parties Current1 DueToRelatedPartiesCurrent1	901370
CY2022Q4	aktx	Due To Related Parties Current1 DueToRelatedPartiesCurrent1	1961953
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20522714
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10801121
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3507268
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	525000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	230650
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	790800
CY2023Q4	us-gaap	Liabilities Liabilities	20753364
CY2022Q4	us-gaap	Liabilities Liabilities	15624189
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23124888
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23124888
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21713248
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19782747
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2312
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1978
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19918594
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17219593
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38171483
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25345566
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	93628
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	29518
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-18156949
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8094477
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2596415
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7529712
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	367877
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	607681
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	367877
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	607681
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1627389
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3924253
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8292072
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8531276
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	3513999
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2023	us-gaap	Operating Expenses OperatingExpenses	13433460
CY2022	us-gaap	Operating Expenses OperatingExpenses	12455529
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-13065583
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-11847848
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	43
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	2114
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	2728101
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	47958
CY2023	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-1186800
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	2100123
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-75000
CY2023	aktx	Fair Value Adjustment To Derivative Liability FairValueAdjustmentToDerivativeLiability	837146
CY2022	aktx	Fair Value Adjustment To Derivative Liability FairValueAdjustmentToDerivativeLiability	92110
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	45945
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	367738
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-15490
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-467073
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	239666
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1314869
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12825917
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13162717
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-74000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-12825917
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13088717
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	64110
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-58925
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12761807
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13147642
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21175668
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21175668
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17711842
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17711842
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1935268
CY2022	aktx	Capital Contribution From Parent CapitalContributionFromParent	1363974
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1152163
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	128161
CY2022	aktx	Issuance Of Pipe Shares IssuanceOfPipeShares	4025000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3419712
CY2022	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	250000
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	3802623
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	452046
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-58925
CY2022	us-gaap	Profit Loss ProfitLoss	-13088717
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8094477
CY2023	aktx	Issuance Of Common Stock Under White Lion Purchase Agreement As A Financing Fee IssuanceOfCommonStockUnderWhiteLionPurchaseAgreementAsAFinancingFee	250000
CY2023	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	105317
CY2023	aktx	Issuance Of Common Stock Upon Exercise Of Convertible Note Warrants From Liability To Equity IssuanceOfCommonStockUponExerciseOfConvertibleNoteWarrantsFromLiabilityToEquity	1786568
CY2023	aktx	Issuance Of Common Stock Upon Exercise Of Pipe Warrants Amount IssuanceOfCommonStockUponExerciseOfPipeWarrantsAmount	4920
CY2023	aktx	Reclassification Of Convertible Note Warrants ReclassificationOfConvertibleNoteWarrants	65469
CY2023	aktx	Capital Contribution From Extinguishment Of Ignyte Sponsor Promissory Note CapitalContributionFromExtinguishmentOfIgnyteSponsorPromissoryNote	211643
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	275418
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	64110
CY2023	us-gaap	Profit Loss ProfitLoss	-12825917
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-18156949
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-12825917
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13088717
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	275418
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	560060
CY2023	us-gaap	Depreciation Depreciation	144045
CY2022	us-gaap	Depreciation Depreciation	151873
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	3513999
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-79495
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-15490
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-467073
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	167073
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	634611
CY2023	aktx	Issuance Of Shares For Financing Fee IssuanceOfSharesForFinancingFee	250000
CY2022	aktx	Issuance Of Shares For Financing Fee IssuanceOfSharesForFinancingFee	250000
CY2023	aktx	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	0
CY2022	aktx	Change In Fair Value Of Convertible Note Payable ChangeInFairValueOfConvertibleNotePayable	1186800
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2100123
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	75000
CY2023	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	837146
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	92110
CY2023	aktx	Accretion Of Convertible Notes Payable AccretionOfConvertibleNotesPayable	2511296
CY2022	aktx	Accretion Of Convertible Notes Payable AccretionOfConvertibleNotesPayable	0
CY2023	aktx	Accretion Of Operating Lease Liability AccretionOfOperatingLeaseLiability	388501
CY2022	aktx	Accretion Of Operating Lease Liability AccretionOfOperatingLeaseLiability	0
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-569403
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	698741
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	7700
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2234921
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	816037
CY2023	aktx	Increase Decrease Inaccrued Expenses And Other Current Liabilities IncreaseDecreaseInaccruedExpensesAndOtherCurrentLiabilities	1600486
CY2022	aktx	Increase Decrease Inaccrued Expenses And Other Current Liabilities IncreaseDecreaseInaccruedExpensesAndOtherCurrentLiabilities	1771097
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-177111
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-87838
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-560150
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	569230
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4758020
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7485625
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	142249
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-142249
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	105317
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5177163
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1029920
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2023	aktx	Repayment Of Insurance Financing Note RepaymentOfInsuranceFinancingNote	921576
CY2022	aktx	Repayment Of Insurance Financing Note RepaymentOfInsuranceFinancingNote	0
CY2023	aktx	Proceeds From Insurance Financing Note ProceedsFromInsuranceFinancingNote	631993
CY2022	aktx	Proceeds From Insurance Financing Note ProceedsFromInsuranceFinancingNote	0
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	300000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
CY2023	aktx	Proceeds From Completion Of Business Combination ProceedsFromCompletionOfBusinessCombination	0
CY2022	aktx	Proceeds From Completion Of Business Combination ProceedsFromCompletionOfBusinessCombination	3910375
CY2023	aktx	Settlement Of Forward Purchase Agreement SettlementOfForwardPurchaseAgreement	0
CY2022	aktx	Settlement Of Forward Purchase Agreement SettlementOfForwardPurchaseAgreement	-3802623
CY2023	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0
CY2022	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	1250298
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4281285
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8135213
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-476735
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	507339
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23793
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-55225
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	894591
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	442477
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	441649
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	894591
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	381649
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	654892
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	60000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	239699
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	441649
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	894591
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	8844
CY2023	aktx	Exchange Of Related Party Loans For Convertible Notes ExchangeOfRelatedPartyLoansForConvertibleNotes	1130775
CY2022	aktx	Exchange Of Related Party Loans For Convertible Notes ExchangeOfRelatedPartyLoansForConvertibleNotes	0
CY2023	aktx	Fair Value Of Warrants Exercised And Reclassified To Additional Paid In Capital FairValueOfWarrantsExercisedAndReclassifiedToAdditionalPaidInCapital	761568
CY2022	aktx	Fair Value Of Warrants Exercised And Reclassified To Additional Paid In Capital FairValueOfWarrantsExercisedAndReclassifiedToAdditionalPaidInCapital	0
CY2023	aktx	Fair Value Of Warrants Reclassified To Additional Paid In Capital FairValueOfWarrantsReclassifiedToAdditionalPaidInCapital	65469
CY2022	aktx	Fair Value Of Warrants Reclassified To Additional Paid In Capital FairValueOfWarrantsReclassifiedToAdditionalPaidInCapital	0
CY2023	aktx	Capital Contribution From Extinguishment Of Ignyte Sponsor Promissory Note CapitalContributionFromExtinguishmentOfIgnyteSponsorPromissoryNote	211643
CY2022	aktx	Capital Contribution From Extinguishment Of Ignyte Sponsor Promissory Note CapitalContributionFromExtinguishmentOfIgnyteSponsorPromissoryNote	0
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	33060
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	450000
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	0
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	211953
CY2023	aktx	Convertible Notes Payable And Derivative Liability Assumed In Business Combination ConvertibleNotesPayableAndDerivativeLiabilityAssumedInBusinessCombination	0
CY2022	aktx	Convertible Notes Payable And Derivative Liability Assumed In Business Combination ConvertibleNotesPayableAndDerivativeLiabilityAssumedInBusinessCombination	1512500
CY2023	aktx	Related Party Loan For Settlement Of Accrued Liability RelatedPartyLoanForSettlementOfAccruedLiability	0
CY2022	aktx	Related Party Loan For Settlement Of Accrued Liability RelatedPartyLoanForSettlementOfAccruedLiability	400000
CY2023	aktx	Shares Issued For Settlement Of Related Party Loan And Accrued Interest SharesIssuedForSettlementOfRelatedPartyLoanAndAccruedInterest	0
CY2022	aktx	Shares Issued For Settlement Of Related Party Loan And Accrued Interest SharesIssuedForSettlementOfRelatedPartyLoanAndAccruedInterest	502740
CY2023	aktx	Shares Issued For Settlement Of Convertible Notes Payable And Accrued Interest SharesIssuedForSettlementOfConvertibleNotesPayableAndAccruedInterest	0
CY2022	aktx	Shares Issued For Settlement Of Convertible Notes Payable And Accrued Interest SharesIssuedForSettlementOfConvertibleNotesPayableAndAccruedInterest	1263099
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4189492
CY2022Q4	aktx	Common Stock Convertible Exchange Ratio CommonStockConvertibleExchangeRatio	2.0719
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-12800000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13100000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates include but are not limited to fair value of the Company's stock, stock-based compensation expense, warrant liability, derivative liability, and discount rates used to establish operating lease liability. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	aktx	Common Stock Convertible Exchange Ratio CommonStockConvertibleExchangeRatio	2.0719
CY2022Q3	aktx	Business Combination Common Stock Shares Outstanding BusinessCombinationCommonStockSharesOutstanding	5750000
CY2022Q4	aktx	Redemption Of Ignyte Shares RedemptionOfIgnyteShares	-5159287
CY2022Q4	aktx	Common Stock Of Ignyte1 CommonStockOfIgnyte1	590713
CY2022Q4	aktx	Ignyte Founder Shares1 IgnyteFounderShares1	1537500
CY2022Q4	aktx	Shares Issued Or Services And Debt Settlement SharesIssuedOrServicesAndDebtSettlement	106150
CY2022Q4	aktx	Total Ignyte Shares1 TotalIgnyteShares1	2234363
CY2022Q4	aktx	Common Stock Issued To Peak Bio Shareholders1 CommonStockIssuedToPeakBioShareholders1	17295044
CY2022Q4	aktx	Business Combination Common Stock Shares Outstanding BusinessCombinationCommonStockSharesOutstanding	19529407
CY2023	aktx	Cash Ignyte Trust And Cash Net Of Redemptions CashIgnyteTrustAndCashNetOfRedemptions	3538766
CY2023	aktx	Restricted Cash Forward Share Purchase Agreement RestrictedCashForwardSharePurchaseAgreement	4551750
CY2023	aktx	Other Assets1 OtherAssets1	692487
CY2023	aktx	Assets Acquired AssetsAcquired	8783003
CY2023	aktx	Fair Value Of Private Warrants FairValueOfPrivateWarrants	450000
CY2023	aktx	Derivative Liability On Forward Share Purchase Agreement1 DerivativeLiabilityOnForwardSharePurchaseAgreement1	80110
CY2023	aktx	Other Liabilities And Accrued Expenses OtherLiabilitiesAndAccruedExpenses	3944592
CY2023	aktx	Liabilities Assumed2 LiabilitiesAssumed2	4474702
CY2023	aktx	Net Assets Acquired NetAssetsAcquired	4308301
CY2023Q4	aktx	Restricted Bank Account Collateral For Credit Card RestrictedBankAccountCollateralForCreditCard	60000
CY2022Q4	aktx	Restricted Bank Account Collateral For Credit Card RestrictedBankAccountCollateralForCreditCard	60000
CY2022Q4	aktx	Restricted Cash Collateral For Secured Letter Of Credit RestrictedCashCollateralForSecuredLetterOfCredit	177000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of credit risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains its cash balances in the form of business checking accounts and money market accounts in the U.S., the balances of which, at times, may exceed federally insured limits. The Federal Deposit Insurance Corporation (“FDIC”) insurance coverage limit is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per depositor, per FDIC-insured bank, per ownership category. Exposure to credit risk is reduced by placing such deposits in high credit quality federally insured financial institutions. Although the Company currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the years ended December 31, 2023 and 2022.</span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	3513999
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.793
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0466
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.751
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0181
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	aktx	Schedule Of Prepaid Expenses And Other Current Assets Table Textblock ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextblock	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prepaid and other current assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid and other current assets consist of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.1%;"></td> <td style="width:1.62%;"></td> <td style="width:1.06%;"></td> <td style="width:12.84%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1.06%;"></td> <td style="width:12.7%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,917,266</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,317,925</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,192</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">244,976</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid and other current assets</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,992,458</span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,562,901</span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1917266
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2317925
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	75192
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	244976
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1992458
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2562901
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	752892
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	848286
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	599784
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	471638
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153108
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	376648
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	43552
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	608846
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3322454
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1364142
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	210762
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	65303
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3576768
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2038291
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	560150
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1750967
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.36
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	486097
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	52213
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.05
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1698754
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.28
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1525334
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.97
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y7M6D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	335646
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	275418
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	560060
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	30000.00
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y25D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	275418
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	560060
CY2021Q4	aktx	Annual Escalations AnnualEscalations	0.03
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	177111
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	786563
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4189492
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10
CY2021Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-05-31
CY2021Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.01
CY2021Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-07-31
CY2021Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.01
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	150000
CY2023Q2	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	448940
CY2023Q2	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	26830
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000
CY2023Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-12-31
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.05
CY2023Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	1199
CY2022Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	50273
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	10
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	46754
CY2023Q2	aktx	Payment Of Commission PaymentOfCommission	125000
CY2022Q4	us-gaap	Financial Guarantee Insurance Contracts Premium Receivable FinancialGuaranteeInsuranceContractsPremiumReceivable	1006342
CY2022Q4	us-gaap	Financial Guarantee Insurance Contracts Premium Received Over Contract Period Premium Receivable Weighted Average Risk Free Discount Rate FinancialGuaranteeInsuranceContractsPremiumReceivedOverContractPeriodPremiumReceivableWeightedAverageRiskFreeDiscountRate	0.072
CY2023Q4	us-gaap	Financial Guarantee Insurance Contracts Premium Receivable FinancialGuaranteeInsuranceContractsPremiumReceivable	631993
CY2023Q4	us-gaap	Financial Guarantee Insurance Contracts Premium Received Over Contract Period Premium Receivable Weighted Average Risk Free Discount Rate FinancialGuaranteeInsuranceContractsPremiumReceivedOverContractPeriodPremiumReceivableWeightedAverageRiskFreeDiscountRate	0.0995
CY2023Q4	aktx	Insurance Financing Payable InsuranceFinancingPayable	631993
CY2022Q4	aktx	Insurance Financing Payable InsuranceFinancingPayable	921576
CY2022Q4	us-gaap	Share Price SharePrice	10.115
CY2022Q4	us-gaap	Escrow Deposit EscrowDeposit	4551750
CY2022Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	375939
CY2022Q4	us-gaap	Share Price SharePrice	10.115
CY2022Q4	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	375939
CY2022Q4	us-gaap	Escrow Deposit Disbursements Related To Property Acquisition1 EscrowDepositDisbursementsRelatedToPropertyAcquisition1	4551750
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	68110
CY2022Q4	us-gaap	Share Price SharePrice	13.05
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.281
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.04
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y1M28D
CY2022	aktx	Changein Fairvalue Of Derivative Liability ChangeinFairvalueOfDerivativeLiability	68110
CY2022	aktx	Changein Fairvalue Of Derivative Liability Forward Purchase Agreement ChangeinFairvalueOfDerivativeLiabilityForwardPurchaseAgreement	0
CY2023	aktx	Changein Fairvalue Of Derivative Liability Forward Purchase Agreement ChangeinFairvalueOfDerivativeLiabilityForwardPurchaseAgreement	0
CY2023Q2	aktx	Common Stock Shares Forfeiture CommonStockSharesForfeiture	1930501
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	13000
CY2023Q3	aktx	Accelerated Purchase Price Discounting Percentage AcceleratedPurchasePriceDiscountingPercentage	0.20
CY2023Q3	aktx	Accelerated Purchase Notice Limit Percentage AcceleratedPurchaseNoticeLimitPercentage	2
CY2023Q4	aktx	Warrant Redemption Price Per Share WarrantRedemptionPricePerShare	0.01
CY2023Q4	aktx	Last Sale Price Of Common Stock LastSalePriceOfCommonStock	18
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	361704
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	678000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-12614259
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-10222781
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-211658
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2939936
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12825917
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13162717
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	3000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-42000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-39000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2701000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1984000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1061000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-639000
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	16297000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1603000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-12535000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4191000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-35000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-74000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0056
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0784
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0486
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0039
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0036
CY2023	aktx	Effective Income Tax Rate Reconciliation Permanent Difference Derivatives EffectiveIncomeTaxRateReconciliationPermanentDifferenceDerivatives	0.0137
CY2022	aktx	Effective Income Tax Rate Reconciliation Permanent Difference Derivatives EffectiveIncomeTaxRateReconciliationPermanentDifferenceDerivatives	-0.0191
CY2023	aktx	Effective Income Tax Rate Reconciliation Permanent Difference Convertible Notes EffectiveIncomeTaxRateReconciliationPermanentDifferenceConvertibleNotes	0.0344
CY2022	aktx	Effective Income Tax Rate Reconciliation Permanent Difference Convertible Notes EffectiveIncomeTaxRateReconciliationPermanentDifferenceConvertibleNotes	0
CY2023	aktx	Effective Income Tax Rate Reconciliation Permanent Difference Interest Expense On Convertible Notes EffectiveIncomeTaxRateReconciliationPermanentDifferenceInterestExpenseOnConvertibleNotes	-0.044
CY2022	aktx	Effective Income Tax Rate Reconciliation Permanent Difference Interest Expense On Convertible Notes EffectiveIncomeTaxRateReconciliationPermanentDifferenceInterestExpenseOnConvertibleNotes	0
CY2023	aktx	Effective Income Tax Rate Reconciliation Return To Provision EffectiveIncomeTaxRateReconciliationReturnToProvision	0.0117
CY2022	aktx	Effective Income Tax Rate Reconciliation Return To Provision EffectiveIncomeTaxRateReconciliationReturnToProvision	0.0883
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.9773
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3184
CY2023	aktx	Effective Income Tax Rate Reconciliation Warrants Issued On Conversion EffectiveIncomeTaxRateReconciliationWarrantsIssuedOnConversion	0
CY2022	aktx	Effective Income Tax Rate Reconciliation Warrants Issued On Conversion EffectiveIncomeTaxRateReconciliationWarrantsIssuedOnConversion	-0.0074
CY2023	aktx	Effective Income Tax Rate Reconciliation Change In Foreign Jurisdiction Tax Rate EffectiveIncomeTaxRateReconciliationChangeInForeignJurisdictionTaxRate	-1.2776
CY2022	aktx	Effective Income Tax Rate Reconciliation Change In Foreign Jurisdiction Tax Rate EffectiveIncomeTaxRateReconciliationChangeInForeignJurisdictionTaxRate	0
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0056
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	2241000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	964000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	839000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	297000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	8886000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	24965000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	375000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	379000
CY2023Q4	aktx	Deferred Tax Assets Foreign Accruals DeferredTaxAssetsForeignAccruals	421000
CY2022Q4	aktx	Deferred Tax Assets Foreign Accruals DeferredTaxAssetsForeignAccruals	936000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1100000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	615000
CY2023Q4	aktx	Capitalized Start Up Costs CapitalizedStartUpCosts	238000
CY2022Q4	aktx	Capitalized Start Up Costs CapitalizedStartUpCosts	209000
CY2023Q4	aktx	Capitalized Research And Development CapitalizedResearchAndDevelopment	725000
CY2022Q4	aktx	Capitalized Research And Development CapitalizedResearchAndDevelopment	437000
CY2023Q4	aktx	Deferred Tax Assets Right Of Use Operating Lease DeferredTaxAssetsRightOfUseOperatingLease	1242000
CY2022Q4	aktx	Deferred Tax Assets Right Of Use Operating Lease DeferredTaxAssetsRightOfUseOperatingLease	1183000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16067000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29985000
CY2023Q4	aktx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	0
CY2022Q4	aktx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	1030000
CY2023Q4	aktx	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	37000
CY2022Q4	aktx	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	88000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	37000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1118000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	16030000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	28867000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16030000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28867000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16000000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28900000
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	300000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12800000
CY2023	aktx	Net Operating Loss Generated Prior To Twenty Twenty Carryforward Term NetOperatingLossGeneratedPriorToTwentyTwentyCarryforwardTerm	P10Y
CY2023	aktx	Net Operating Loss Generated After Twenty Twenty Carryforward Term NetOperatingLossGeneratedAfterTwentyTwentyCarryforwardTerm	P15Y
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235774
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	381649
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1095939
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1992458
CY2024Q2	us-gaap	Assets Current AssetsCurrent	1331713
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2374107
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31807
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	153108
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	60000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	60000
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11136
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9200
CY2024Q2	us-gaap	Assets Assets	1434656
CY2023Q4	us-gaap	Assets Assets	2596415
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5471565
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5862435
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4402454
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3576768
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4603516
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4439235
CY2024Q2	aktx	Insurance Financing Note InsuranceFinancingNote	0
CY2023Q4	aktx	Insurance Financing Note InsuranceFinancingNote	631993
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1853694
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	361704
CY2024Q2	aktx	Promissory Note Current PromissoryNoteCurrent	350000
CY2023Q4	aktx	Promissory Note Current PromissoryNoteCurrent	350000
CY2024Q2	aktx	Due To Related Parties Current1 DueToRelatedPartiesCurrent1	1651370
CY2023Q4	aktx	Due To Related Parties Current1 DueToRelatedPartiesCurrent1	901370
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	24025358
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20522714
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	230650
CY2024Q2	us-gaap	Liabilities Liabilities	24025358
CY2023Q4	us-gaap	Liabilities Liabilities	20753364
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23124888
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23124888
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23124888
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23124888
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	2312
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2312
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19949103
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19918594
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-42684051
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38171483
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	141934
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	93628
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-22590702
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-18156949
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1434656
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2596415
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13854
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13854
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	108643
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	371154
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	178912
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1084260
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1281985
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2299058
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3416544
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5303880
CY2024Q2	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2023Q2	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	3513999
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	1390628
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2670212
	us-gaap	Operating Expenses OperatingExpenses	3595456
	us-gaap	Operating Expenses OperatingExpenses	9902139
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1390628
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2670212
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3595456
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9888285
CY2024Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	1
CY2023Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	20
	us-gaap	Interest And Other Income InterestAndOtherIncome	3
	us-gaap	Interest And Other Income InterestAndOtherIncome	26
CY2024Q2	us-gaap	Interest Expense Other InterestExpenseOther	448962
CY2023Q2	us-gaap	Interest Expense Other InterestExpenseOther	998548
	us-gaap	Interest Expense Other InterestExpenseOther	772102
	us-gaap	Interest Expense Other InterestExpenseOther	1059934
CY2024Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	0
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-712857
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-187857
CY2024Q2	aktx	Fair Value Adjustment To Derivative Liability FairValueAdjustmentToDerivativeLiability	-238289
CY2023Q2	aktx	Fair Value Adjustment To Derivative Liability FairValueAdjustmentToDerivativeLiability	-548233
	aktx	Fair Value Adjustment To Derivative Liability FairValueAdjustmentToDerivativeLiability	-352998
	aktx	Fair Value Adjustment To Derivative Liability FairValueAdjustmentToDerivativeLiability	-560233
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-29
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-409
CY2024Q2	aktx	Cancellation Of Trade Liability CancellationOfTradeLiability	0
CY2023Q2	aktx	Cancellation Of Trade Liability CancellationOfTradeLiability	0
	aktx	Cancellation Of Trade Liability CancellationOfTradeLiability	207967
	aktx	Cancellation Of Trade Liability CancellationOfTradeLiability	0
CY2024Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1014368
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1014368
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-687239
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3274015
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-917112
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2822775
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2077867
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5944227
	us-gaap	Net Income Loss NetIncomeLoss	-4512568
	us-gaap	Net Income Loss NetIncomeLoss	-12711060
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	15720
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	10366
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	48305
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	81942
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2062147
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5933861
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4464263
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12629118
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23124888
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23124888
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20254118
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20254118
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23124888
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23124888
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20047100
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20047100
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.2
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.2
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8094477
CY2023Q1	aktx	Issuance Of Common Stock Under White Lion Purchase Agreement As A Financing Fee IssuanceOfCommonStockUnderWhiteLionPurchaseAgreementAsAFinancingFee	250000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	165007
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	71576
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-6766834
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-14374728
CY2023Q2	aktx	Issuance Of Common Stock Upon Exercise Of Convertible Note Warrants From Liability To Equity IssuanceOfCommonStockUponExerciseOfConvertibleNoteWarrantsFromLiabilityToEquity	644261
CY2023Q2	aktx	Capital Contribution From Extinguishment Of Ignyte Sponsor Promissory Note CapitalContributionFromExtinguishmentOfIgnyteSponsorPromissoryNote	211643
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	133437
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	10366
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-5944227
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-19319248
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-18156949
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	30509
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	32586
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-2434701
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-20528555
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	15720
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-2077867
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-22590702
	us-gaap	Net Income Loss NetIncomeLoss	-4512568
	us-gaap	Net Income Loss NetIncomeLoss	-12711060
	us-gaap	Share Based Compensation ShareBasedCompensation	30509
	us-gaap	Share Based Compensation ShareBasedCompensation	298444
	us-gaap	Depreciation Depreciation	53585
	us-gaap	Depreciation Depreciation	77238
	aktx	Accretion Of Convertible Notes Payable AccretionOfConvertibleNotesPayable	423283
	aktx	Accretion Of Convertible Notes Payable AccretionOfConvertibleNotesPayable	994944
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	187857
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-352998
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-560233
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1014368
	aktx	Cancellation Of Trade Liability CancellationOfTradeLiability	207967
	aktx	Cancellation Of Trade Liability CancellationOfTradeLiability	0
	aktx	Issuance Of Shares For Financing Fee IssuanceOfSharesForFinancingFee	0
	aktx	Issuance Of Shares For Financing Fee IssuanceOfSharesForFinancingFee	250000
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	3513999
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1216
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-79495
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	167073
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-895591
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1262146
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1936
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-128820
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1517293
	aktx	Increase Decrease Inaccrued Expenses And Other Current Liabilities IncreaseDecreaseInaccruedExpensesAndOtherCurrentLiabilities	837409
	aktx	Increase Decrease Inaccrued Expenses And Other Current Liabilities IncreaseDecreaseInaccruedExpensesAndOtherCurrentLiabilities	647879
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	164281
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	26734
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-230650
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-560150
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2323069
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2673507
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	66500
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	66500
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	400000
	aktx	Repayment Of Insurance Financing Payable RepaymentOfInsuranceFinancingPayable	631993
	aktx	Repayment Of Insurance Financing Payable RepaymentOfInsuranceFinancingPayable	691182
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2116667
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2028049
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-139902
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-645458
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5973
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25236
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	441649
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	894591
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295774
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	274369
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235774
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	214369
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	60000
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	60000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295774
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	274369
	us-gaap	Interest Paid Net InterestPaidNet	56683
	us-gaap	Interest Paid Net InterestPaidNet	0
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
	aktx	Exchange Of April2023 Convertible Notes For December2023 Convertiblenotes ExchangeOfApril2023ConvertibleNotesForDecember2023Convertiblenotes	250600
	aktx	Exchange Of April2023 Convertible Notes For December2023 Convertiblenotes ExchangeOfApril2023ConvertibleNotesForDecember2023Convertiblenotes	0
	aktx	Capital Contribution From Extinguishment Of Ignyte Sponsor Promissory Note CapitalContributionFromExtinguishmentOfIgnyteSponsorPromissoryNote	0
	aktx	Capital Contribution From Extinguishment Of Ignyte Sponsor Promissory Note CapitalContributionFromExtinguishmentOfIgnyteSponsorPromissoryNote	211643
	aktx	Exchange Of Related Party Loans For Convertible Notes ExchangeOfRelatedPartyLoansForConvertibleNotes	0
	aktx	Exchange Of Related Party Loans For Convertible Notes ExchangeOfRelatedPartyLoansForConvertibleNotes	1130775
	aktx	Fair Value Of Warrants With Related Party FairValueOfWarrantsWithRelatedParty	0
	aktx	Fair Value Of Warrants With Related Party FairValueOfWarrantsWithRelatedParty	786967
	aktx	Fair Value Of Warrants Issued With Convertible Notes FairValueOfWarrantsIssuedWithConvertibleNotes	0
	aktx	Fair Value Of Warrants Issued With Convertible Notes FairValueOfWarrantsIssuedWithConvertibleNotes	1615194
	aktx	Fair Value Of Derivativeissued With Convertible Notes FairValueOfDerivativeissuedWithConvertibleNotes	0
	aktx	Fair Value Of Derivativeissued With Convertible Notes FairValueOfDerivativeissuedWithConvertibleNotes	849146
	aktx	Fair Value Of Warrants Exercised And Reclassified To Additional Paid In Capital FairValueOfWarrantsExercisedAndReclassifiedToAdditionalPaidInCapital	0
	aktx	Fair Value Of Warrants Exercised And Reclassified To Additional Paid In Capital FairValueOfWarrantsExercisedAndReclassifiedToAdditionalPaidInCapital	244261
	us-gaap	Net Income Loss NetIncomeLoss	-4500000
	us-gaap	Net Income Loss NetIncomeLoss	-12700000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:1.04%;text-indent:3.099%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates include but are not limited to fair value of the Company’s stock, stock-based compensation expense, warrant liability, derivative liability, and discount rates used to establish operating lease liability. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.</span></p>
CY2024Q2	aktx	Restricted Bank Account Collateral For Credit Card RestrictedBankAccountCollateralForCreditCard	60000
CY2023Q4	aktx	Restricted Bank Account Collateral For Credit Card RestrictedBankAccountCollateralForCreditCard	60000
CY2024Q2	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	3513999
	aktx	Schedule Of Prepaid Expenses And Other Current Assets Table Textblock ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextblock	<p style="margin-left:1.04%;text-indent:3.099%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid and other current assets consist of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.1%;"></td> <td style="width:1.62%;"></td> <td style="width:1.06%;"></td> <td style="width:12.84%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1.06%;"></td> <td style="width:12.7%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid directors and officers insurance current policies</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">489,093</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,222,734</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid directors and officers insurance run-off policies</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">572,362</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">638,404</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other prepaid expenses</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,484</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,128</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,192</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid and other current assets</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,095,939</span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,992,458</span></p></td> <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	489093
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1222734
CY2024Q2	aktx	Prepaid Insurance Run Off Policies PrepaidInsuranceRunOffPolicies	572362
CY2023Q4	aktx	Prepaid Insurance Run Off Policies PrepaidInsuranceRunOffPolicies	638404
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	34484
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	56128
CY2024Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	75192
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1095939
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1992458
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	66982
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	43552
CY2024Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3840473
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3322454
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	494999
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	210762
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4402454
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3576768
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1698754
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.28
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	335646
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.51
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1363108
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.46
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y10M24D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1363108
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.46
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y10M24D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	335646
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.793
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0466
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	133437
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30509
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	298444
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	133437
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30509
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	298444
CY2021Q4	aktx	Annual Escalations AnnualEscalations	0.03
CY2021Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-05-31
CY2021Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.01
CY2021Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-07-31
CY2021Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.01
	us-gaap	Repayments Of Debt RepaymentsOfDebt	150000
CY2023Q2	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	448940
CY2023Q2	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	26830
CY2023Q2	aktx	Payment Of Commission PaymentOfCommission	125000
CY2022Q4	us-gaap	Financial Guarantee Insurance Contracts Premium Receivable FinancialGuaranteeInsuranceContractsPremiumReceivable	1006342
CY2022Q4	us-gaap	Financial Guarantee Insurance Contracts Premium Received Over Contract Period Premium Receivable Weighted Average Risk Free Discount Rate FinancialGuaranteeInsuranceContractsPremiumReceivedOverContractPeriodPremiumReceivableWeightedAverageRiskFreeDiscountRate	0.072
CY2023Q4	us-gaap	Financial Guarantee Insurance Contracts Premium Receivable FinancialGuaranteeInsuranceContractsPremiumReceivable	631993
CY2023Q4	us-gaap	Financial Guarantee Insurance Contracts Premium Received Over Contract Period Premium Receivable Weighted Average Risk Free Discount Rate FinancialGuaranteeInsuranceContractsPremiumReceivedOverContractPeriodPremiumReceivableWeightedAverageRiskFreeDiscountRate	0.0995
CY2024Q2	aktx	Insurance Financing Payable InsuranceFinancingPayable	0
CY2023Q2	aktx	Common Stock Shares Forfeiture CommonStockSharesForfeiture	1930501
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	13000
CY2023Q3	aktx	Accelerated Purchase Price Discounting Percentage AcceleratedPurchasePriceDiscountingPercentage	0.20
CY2023Q3	aktx	Accelerated Purchase Notice Limit Percentage AcceleratedPurchaseNoticeLimitPercentage	2
CY2024Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1853694
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	361704
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2024Q3	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	32800

Files In Submission

Name	View Source	Status
0000950170-24-104428-index-headers.html	Edgar Link	pending
0000950170-24-104428-index.html	Edgar Link	pending
0000950170-24-104428.txt	Edgar Link	pending
0000950170-24-104428-xbrl.zip	Edgar Link	pending
aktx-20240906.htm	Edgar Link	pending
aktx-20240906.xsd	Edgar Link	pending
aktx-ex23_1.htm	Edgar Link	pending
aktx-ex99_1.htm	Edgar Link	pending
aktx-ex99_2.htm	Edgar Link	pending
aktx-ex99_3.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
aktx-20240906_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AKTX
Akari Therapeutics Plc Stock $aktx

2024 Q2 Form 8-K Financial Statement

#000095017024104428 Filed on September 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKTX Akari Therapeutics Plc Stock $aktx

2024 Q2 Form 8-K Financial Statement

#000095017024104428 Filed on September 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKTX
Akari Therapeutics Plc Stock $aktx